ARCHIVES

Iniparib Doesn’t Meet Survival, PFS Endpoints In Phase III Trial in Triple-Negative Breast Cancer

This article is from The Cancer Letter archive.

Vol. 34 No. 2 | February 25, 2011

Download PDF Visit The Full Archive

Related Articles

Gramm-Rudman Cut Facing NCI Could Take $85 Million

October 20, 1989

Trastuzumab Showed Improved Survival In Stage IV Breast Cancer with CNS Metastases

August 26, 2011

NCI To Study Whether It Gets The Most From Advisors.

March 8, 2002

Spending Freeze Could Harm Medical Research, ACS Advocacy Affiliate Says

January 29, 2010

New Mammography Guidelines Cut Uses By Women Under 50 t 25%

July 29, 1977

Funding Opportunities: Career Development Award In Leukemia

July 23, 1999